Low dose intravenous immunoglobulin in systemic lupus erythematosus: Analysis of 62 cases

Israel Medical Association Journal

Volumn 10, Issue 1, 2008, Pages 55-57

  Sherer, Yaniv ^a,f   Kuechler, Sabine ^a,f   Scali, Juan Jose ^b   Rovensky, Josef ^c   Levy, Yair ^d   Zandman Goddard, Gisele ^e,f   Shoenfeld, Yehuda ^a,f  

^a SHEBA MEDICAL CENTER   (Israel)

^b HOSPITAL DURAND   (Argentina)

^c NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

^d MEIR MEDICAL CENTER   (Israel)

^e WOLFSON MEDICAL CENTER   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

Intravenous immunoglobulin; Low dose; SLEDAI; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ADULT; ALOPECIA; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG INDICATION; FEMALE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULITIS; DOSE RESPONSE; FEVER; HEMATURIA; MOUTH ULCER; PERICARDITIS; PLEURISY; RASH; RETROSPECTIVE STUDY;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; FEVER; HEMATURIA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; ORAL ULCER; PERICARDITIS; PLEURISY; RETROSPECTIVE STUDIES;

EID: 41149157478     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Krause I, Blank M, Kopolovic J, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995;22:1068-74.
2. Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 2006;5:153-5.
3. Strand V. Lessons learned from clinical trials in SLE. Autoimmun Rev 2007;6:209-14.
4. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989;53:303-10.
5. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996;23:71-5.
6. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long term I.V.Ig treatment in systemic lupus erythematosus. Clin Exp Rheum 1994;12:163-8.
7. Akashi K, Nagasawa K, Mayumi T, Yokota E, Oochi N, Kusaba T. Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol 1990;17:375-9.
8. Ben-Chetrit E, Putterman C, Naparstek Y. Lupus refractory pleural effusion: transient response to intravenous immunoglobulins. J Rheumatol 1991;18:1635-7.
9. Sherer Y, Levy Y, Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 1999;18:238-40.
10. Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000;29:321-7.
11. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999;8:705-12.
12. Kamali S, Cefle A, Sayarlioglu M, et al. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatol Int 2005;25:211-14.
13. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005;29:219-28.
14. Zandman-Goddard G, Krauthammer A, Shoenfeld Y. The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases. Exp Rev Clin Immunol 2007;3:773-80.
15. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6:257-9.
16. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84.
17. Sherer Y, Levy Y, Fabrizzi F, Shoenfeld Y. Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today 1999;35:513-18.
18. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 2001;62:133-7.
19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354:569-70.
21. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002;14:1303-11.
22. Konova E, Atanasova M, Stoykov S, Velkova A, Shoenfeld Y. Idiotypic and anti-idiotypic elastin autoantibodies: implications for IVIg and pregnancy loss. J Autoimmun 2007;28:46-54.
23. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007;179:5571-5.
24. Le Pottier L, Bendaoud B, Dueymes M, et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 2007;27:257-65.
25. Onouchi Z, Yanagisawa M, Hirayama T, Kiyosawa N, Matsuda H, Nakashima M. Optimal dosage and differences in therapeutic efficacy of IVIG in Kawasaki disease. Acta Paediatr Jpn 1995;37:40-6.